Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer.

@article{Sargent2010DefectiveMR,
  title={Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer.},
  author={Daniel J. Sargent and Silvia Marsoni and Genevi{\'e}ve Monges and Stephen N. Thibodeau and Roberto M. Labianca and Stanley R. Hamilton and Amy J. French and Brian F. Kabat and Nathan R. Foster and Valter Torri and Christine Ann Ribic and Axel F Grothey and Malcolm J. Moore and Alberto Zaniboni and J E Seitz and Frank A. Sinicrope and Steven Gallinger},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2010},
  volume={28 20},
  pages={3219-26}
}
PURPOSE Prior reports have indicated that patients with colon cancer who demonstrate high-level microsatellite instability (MSI-H) or defective DNA mismatch repair (dMMR) have improved survival and receive no benefit from fluorouracil (FU) -based adjuvant therapy compared with patients who have microsatellite-stable or proficient mismatch repair (pMMR) tumors. We examined MMR status as a predictor of adjuvant therapy benefit in patients with stages II and III colon cancer. METHODS MSI assay… CONTINUE READING
Highly Influential
This paper has highly influenced a number of papers. REVIEW HIGHLY INFLUENTIAL CITATIONS